Evogene宣布子公司Biomica旗下理性设计活菌产品BMC128联合纳武利尤单抗完成1期临床研究

投资观察
Jun 02

Evogene Ltd. 近日宣布,其子公司Biomica开发的理性设计活菌产品BMC128,与纳武利尤单抗联合用药的1期临床研究已成功完成。该研究达到了主要终点,显示出良好的安全性特征,且未观察到剂量限制性毒性。研究结果证实了BMC128联合疗法具有有利的安全性,并初步显示出临床活性的积极信号。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10